Latest Breaking News On - Primary outcomes - Page 1 : comparemela.com

American College of Cardiology ACC 24 Late-breaking Science and Guidelines Session Summary

American College of Cardiology ACC 24 Late-breaking Science and Guidelines Session Summary
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesAnniversary of american college cardiologySymposium of the heart rhythm societyClinical researchMedication management program to reduceAmerican heart associationAmerican college of cardiology sessionRisk factors among national football league alumniAmerican college of cardiologyGeorgia world congress centerHealth status in heart failure clinic trialOutcomes after technology assisted nonprescription rosuvastatin administrationAmerican collegeAnnual scientific sessionGeorgia world congressCardiovascular care

SEL-212 Shows Significant Response Rates, sUA Reductions in Patients with Gout

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.

United statesSan diegoHerbert barafGeorge washington universityAmerican college of rheumatologyBone researchNational institute of arthritisNational instituteSkin diseasesGout refractoryConventional treatmentPrimary outcomesTwo randomizedDouble blindMulticenter phaseAmerican college

TCT23 Late-breakers: Full Schedule Announced

Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Oct. 24, 25 and 26

United statesSan franciscoSuzannev arnoldDavide kandzariRobertl smithDavidh adamsAmitn voraSusheelk kodaliJoanna chikweSuzannej baronFiras zahrAnitaw asgarTobias kochMirvat alasnagRoberto bonowRobertw yeh

Global Idiopathic Pulmonary Fibrosis Market Report 2022 - Strategic Opportunities Windows and Assessment of Unmet Needs

/PRNewswire/ The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to.

United kingdomBoehringer ingelheim pharma gmbChong kun dangEsbriet pirfenidoneBoehringer ingelheim gmbChongkun dangpharmaceuticalPrometic lifesciencesOfev nintedanibLaura woodCelgene corporationNitto denko corporationBiogen incBoehringer ingelheim pharma gmbh coNational organization for rare disorderProduct development innovationClinical development

Global Idiopathic Pulmonary Fibrosis Market Report 2022 - Strategic Opportunities Windows and Assessment of Unmet Needs

/PRNewswire/ The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to.

United kingdomBoehringer ingelheim pharma gmbChong kun dangEsbriet pirfenidoneBoehringer ingelheim gmbChongkun dangpharmaceuticalPrometic lifesciencesOfev nintedanibLaura woodCelgene corporationNitto denko corporationBiogen incBoehringer ingelheim pharma gmbh coNational organization for rare disorderProduct development innovationClinical development